Equity valuations seem reasonable, but watch out for mean-revision of earnings growth.

Utility of ETFs for institutional investors remains somewhat limited, but has increased.

Valuations make the case for overweighting the very largest firms within a U.S. equity allocation.

Product innovation brings new opportunities, but also can significantly alter key performance drivers.